Evidence for downregulation of the negative regulator SPRED2 in clinical prostate cancer

British Journal of Cancer

Volumn 108, Issue 3, 2013, Pages 597-601

  Kachroo, N ^a   Valencia, T ^a   Warren, A Y ^b   Gnanapragasam, V J ^a  

^a UNIVERSITY OF CAMBRIDGE   (United Kingdom)

^b ADDENBROOKE S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

MESSENGER RNA; SPRED 1 PROTEIN; SPRED 2 PROTEIN; TRANSCRIPTION FACTOR; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ARTICLE; CONTROLLED STUDY; DOWN REGULATION; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROSTATE CANCER; REAL TIME POLYMERASE CHAIN REACTION; SCORING SYSTEM; SIGNAL TRANSDUCTION;

BLOTTING, WESTERN; CELL MOVEMENT; CELL PROLIFERATION; COHORT STUDIES; DOWN-REGULATION; DUAL SPECIFICITY PHOSPHATASE 1; HUMANS; INTRACELLULAR SIGNALING PEPTIDES AND PROTEINS; MALE; MEMBRANE PROTEINS; NEOPLASM GRADING; PROGNOSIS; PROSTATIC HYPERPLASIA; PROSTATIC NEOPLASMS; REAL-TIME POLYMERASE CHAIN REACTION; RECEPTORS, INTERLEUKIN; REPRESSOR PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR CELLS, CULTURED;

EID: 84875212131     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.507     Document Type: Article

References (15)

1. Brognard J, Hunter T (2011) Protein kinase signaling networks in cancer. Curr Opin Genet Dev 21: 4-11.
2. Bundschu K, Walter U, Schuh K (2007) Getting a first clue about SPRED functions. Bioessays 29: 897-907.
3. Darby S, Murphy T, Thomas H, Robson CN, Leung HY, Mathers ME, Gnanapragasam VJ (2009) Similar expression to FGF (Sef) inhibits fibroblast growth factor-induced tumourigenic behaviour in prostate cancer cells and is down-regulated in aggressive clinical disease. Br J Cancer 101: 1891-1899.
4. Ma XN, Liu XY, Yang YF, Xiao FJ, Li QF, Yan J, Zhang QW, Wang LS, Li XY, Wang H (2011) Regulation of human hepatocellular carcinoma cells by Spred2 and correlative studies on its mechanism. Biochem Biophys Res Commun 410: 803-808.
5. Murphy T, Hori S, Sewell J, Gnanapragasam VJ (2010) Expression and functional role of negative signalling regulators in tumour development and progression. Int J Cancer 127: 2491-2499.
6. Popa I, Fradet Y, Beaudry G, Hovington H, Beaudry G, Têtu B (2007) Identification of PCA3 (DD3) in prostatic carcinoma by in situ hybridization. Mod Pathol 20: 1121-1127.
7. Rauhala HE, Porkka KP, Tolonen TT, Martikainen PM, Tammela TL, Visakorpi T (2005) Dual-specificity phosphatase 1 and serum/glucocorticoid-regulated kinase are downregulated in prostate cancer. Int J Cancer 117: 738-745.
8. Rogerson L, Darby S, Jabbar T, Mathers ME, Leung HY, Robson CN, Sahadevan K, O'Toole K, Gnanapragasam VJ (2008) Application of transcript profiling in formalin-fixed paraffin-embedded diagnostic prostate cancer needle biopsies. BJU Int 102: 364-370.
9. Ruizeveld de Winter JA, Janssen PJ, Sleddens HM, Verleun-Mooijman MC, Trapman J, Brinkmann AO, Santerse AB, Schröder FH, van der Kwast TH (1994) Androgen receptor status in localized and locally progressive hormone refractory human prostate cancer. Am J Pathol 144: 735-746.
10. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, Arora VK, Kaushik P, Cerami E, Reva B, Antipin Y, Mitsiades N, Landers T, Dolgalev I, Major JE, Wilson M, Socci ND, Lash AE, Heguy A, Eastham JA, Scher HI, Reuter VE, Scardino PT, Sander C, Sawyers CL, Gerald WL (2010) Integrative genomic profiling of human prostate cancer. Cancer Cell 18: 11-22.
11. Valencia T, Joseph A, Kachroo N, Darby S, Meakin S, Gnanapragasam VJ (2011) Role and expression of FRS2 and FRS3 in prostate cancer. BMC Cancer 11: 484.
12. van Leenders GJ, Dukers D, Hessels D, van den Kieboom SW, Hulsbergen CA, Witjes JA, Otte AP, Meijer CJ, Raaphorst FM (2007) Polycomb-group oncogenes EZH2, BMI1, and RING1 are overexpressed in prostate cancer with adverse pathologic and clinical features. Eur Urol 52: 455-463.
13. Wakioka T, Sasaki A, Kato R, Shouda T, Matsumoto A, Miyoshi K, Tsuneoka M, Komiya S, Baron R, Yoshimura A (2001) Spred is a Sprouty-related suppressor of Ras signalling. Nature 412: 647-651.
14. Weir EG, Partin AW, Epstein JI (2000) Correlation of serum prostate specific antigen and quantitative immunohistochemistry. J Urol 163: 1739-1742.
15. Yoshida T, Hisamoto T, Akiba J, Koga H, Nakamura K, Tokunaga Y, Hanada S, Kumemura H, Maeyama M, Harada M, Ogata H, Yano H, Kojiro M, Ueno T, Yoshimura A, Sata M (2006) Spreds inhibitors of the Ras/ERK signal transduction, are dysregulated in human hepatocellular carcinoma and linked to the malignant phenotype of tumors. Oncogene 25: 6056-6066.